Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma.

MLA

Zhou, Jin, et al. “Pan-ERBB Kinase Inhibition Augments CDK4/6 Inhibitor Efficacy in Oesophageal Squamous Cell Carcinoma.” Gut, vol. 71, no. 4, Apr. 2022, pp. 665–75. EBSCOhost, https://doi.org/10.1136/gutjnl-2020-323276.

APA

Zhou, J., Wu, Z., Zhang, Z., Goss, L., McFarland, J., Nagaraja, A., Xie, Y., Gu, S., Peng, K., Zeng, Y., Zhang, X., Long, H., Nakagawa, H., Rustgi, A., Diehl, J. A., Meyerson, M., Wong, K.-K., & Bass, A. (2022). Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. Gut, 71(4), 665–675. https://doi.org/10.1136/gutjnl-2020-323276

Chicago

Zhou, Jin, Zhong Wu, Zhouwei Zhang, Louisa Goss, James McFarland, Ankur Nagaraja, Yingtian Xie, et al. 2022. “Pan-ERBB Kinase Inhibition Augments CDK4/6 Inhibitor Efficacy in Oesophageal Squamous Cell Carcinoma.” Gut 71 (4): 665–75. doi:10.1136/gutjnl-2020-323276.